Compare Lattice Semiconductor Corporation Common Stock (LSCC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lattice Semiconductor Corporation Common Stock vs Repligen Corporation Common Stock — how do they compare? Lattice Semiconductor Corporation Common Stock trades at $113.11 (market cap $17.90B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Lattice Semiconductor Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Lattice Semiconductor Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lattice Semiconductor Corporation Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| LSCC | RGEN | |
|---|---|---|
Market Cap | $17.90B | $11.14B |
Volume | 1,042,232 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $155.27 | $194.57 |
52-Week Low | $61.73 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $17.77B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lattice Semiconductor (LSCC) trades at $121.15, down 1.38% today, with a bullish technical signal from moving averages. The company shows strong revenue growth projections from $523M in 2025 to $651M in 2026, though current valuation metrics remain elevated with a P/E of 504.2. Recent news highlights leadership in AI infrastructure security and new FPGA product launches, supported by overwhelmingly positive analyst sentiment with 88% buy ratings.
LSCC presents growth potential through AI-driven semiconductor demand and expanding product portfolio, but faces risks from high valuations and competitive pressures. The consensus price target of $162.14 suggests 34% upside, though investors should monitor execution on projected margin expansion from 0.58% to 5.57% net profit margin.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lattice Semiconductor Corporation Common Stock
Lattice Semiconductor develops low-power programmable chips, known as FPGAs. Its products are used in communications, computing, industrial, and automotive applications.
Read more on LSCC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
